TPT consists of the biologically active N-terminal 34 amino acids of human parathyroid hormone (PTH) (Figure 1) and is approved in the USA for the treatment of postmenopausal osteoporosis in patients at high risk of bone fracture. The gene discussed is PTH; the disease is bone fracture.